Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different vancomycin dose comparison in ICU patients
IRCT201710109014N194Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vancomycin in meningitis, endocarditis (IE), sepsis and 3 more (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Plasma concentration of vancomycin. Started Oct 2017; status: completed.
02
Drugs
vancomycin
03
Conditions
meningitisendocarditis (IE)sepsisosteomyelitis (OM)Staphylococcosis
Beyond the preview
Go deeper on IRCT201710109014N194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201710109014N194.